drugset / Trial / NCT01124656

Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes

NCT01124656

Phase 3 Terminated 26 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and tolerability of pioglitazone-azilsartan, once daily (QD), in patients with type 2 diabetes mellitus.

Timeline

Start
2006-09
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan Unknown 20 mg Oral
Subject Pioglitazone Small molecule 30 mg Oral
Subject Pioglitazone Small molecule 45 mg Oral